Molecular mechanisms of Alzheimer's disease: From therapeutic targets to promising drugs

Basit Öğe Kaydı
dc.authoridAlan Albayrak, Elif/0000-0001-9636-4068
dc.authoridSevin, Gulnur/0000-0003-4814-9245
dc.authorscopusid57329388100
dc.authorscopusid6508120465
dc.authorscopusid8970943500
dc.contributor.authorAlan, Elif
dc.contributor.authorKerry, Zeliha
dc.contributor.authorSevin, Gulnur
dc.date.accessioned2024-08-25T18:36:31Z
dc.date.available2024-08-25T18:36:31Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractAlzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive impairment so widespread that it interferes with a person's ability to complete daily activities. AD is becoming increasingly common, and it is estimated that the number of patients will reach 152 million by 2050. Current treatment options for AD are symptomatic and have modest benefits. Therefore, considering the human, social, and economic burden of the disease, the development of drugs with the potential to alter disease progression has become a global priority. In this review, the molecular mechanisms involved in the pathology of AD were evaluated as therapeutic targets. The main aim of the review is to focus on new knowledge about mitochondrial dysfunction, oxidative stress, and neuronal transmission in AD, as well as a range of cellular signaling mechanisms and associated treatments. Important molecular interactions leading to AD were described in amyloid cascade and in tau protein function, oxidative stress, mitochondrial dysfunction, cholinergic and glutamatergic neurotransmission, cAMP-regulatory element-binding protein (CREB), the silent mating type information regulation 2 homolog 1 (SIRT-1), neuroinflammation (glial cells), and synaptic alterations. This review summarizes recent experimental and clinical research in AD pathology and analyzes the potential of therapeutic applications based on molecular disease mechanisms.en_US
dc.identifier.doi10.1111/fcp.12861
dc.identifier.issn0767-3981
dc.identifier.issn1472-8206
dc.identifier.pmid36576325en_US
dc.identifier.scopus2-s2.0-85146357257en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1111/fcp.12861
dc.identifier.urihttps://hdl.handle.net/11454/100669
dc.identifier.wosWOS:000914008400001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofFundamental & Clinical Pharmacologyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectacetylcholineen_US
dc.subjectAlzheimer's diseaseen_US
dc.subjectamyloiden_US
dc.subjectsynaptic transmissionen_US
dc.subjectAmyloid-Beta-Peptideen_US
dc.subjectProtein-Kinase-Cen_US
dc.subjectN-Sh Cellsen_US
dc.subjectOxidative Stressen_US
dc.subjectPhosphorylated Tauen_US
dc.subjectMitochondrial Dysfunctionen_US
dc.subjectPrecursor-Proteinen_US
dc.subjectNmda Receptorsen_US
dc.subjectTransgenic Mouseen_US
dc.subjectNeuronal Cellsen_US
dc.titleMolecular mechanisms of Alzheimer's disease: From therapeutic targets to promising drugsen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu